CB-6644
| 中文名稱(chēng) | CB-6644 |
|---|---|
| 中文同義詞 | 化合物CB-6644;5-氯-2-乙氧基-4-氟-N-(4-((3-(甲氧基甲基)-1-氧代-6,7-二氫-1H,5H-苯并[C]吡唑并[1,2-A][1,2]二氮雜卓-2-基)氨基)-2,2-二甲基-4-氧代丁基)苯甲酰胺;化合物CB-6644,10 MM DMSO 溶液 |
| 英文名稱(chēng) | CB-6644 |
| 英文同義詞 | CB-6644;CB-6644 (CB6644;Chb-M';CB6644,CB-6644,Inhibitor,CB 6644,inhibit;Benzamide, 5-chloro-N-[4-[[6,7-dihydro-3-(methoxymethyl)-1-oxo-1H,5H-pyrazolo[1,2-a][1,2]benzodiazepin-2-yl]amino]-2,2-dimethyl-4-oxobutyl]-2-ethoxy-4-fluoro-;5-Chloro-2-ethoxy-4-fluoro-N-(4-((3-(methoxymethyl)-1-oxo-6,7-dihydro-1H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-2-yl)amino)-2,2-dimethyl-4-oxobutyl)benzamide;CB-6644, 10 mM in DMSO |
| CAS號(hào) | 2316817-88-4 |
| 分子式 | C29H34ClFN4O5 |
| 分子量 | 573.06 |
| EINECS號(hào) | |
| 相關(guān)類(lèi)別 | |
| Mol文件 | 2316817-88-4.mol |
| 結(jié)構(gòu)式 |  |
CB-6644 性質(zhì)
| 密度 | 1.34±0.1 g/cm3(Predicted) |
|---|---|
| 儲(chǔ)存條件 | Store at -20°C |
| 溶解度 | DMSO:100.0(最大濃度 mg/mL);174.5(最大濃度 mM) |
| 形態(tài) | 固體 |
| 酸度系數(shù)(pKa) | 13.13±0.20(Predicted) |
| 顏色 | 白色至淺黃色 |
CB-6644 一種選擇性的 RUVBL1/2 復(fù)合體抑制劑。抑制 RUVBL1/2 的 ATP 酶活性，IC50 為 15 nM。具有抗癌活性。
CB-6644 (20 μM) interacts with the RUVBL1/2 complex in Ramos cells.
CB-6644 (0.001-10 μM; 72 hours) potently kills 123 cell lines (including HCT116, NCI-1975, and HT29 cells) with an EC
50
range of 41 to 785 nM.
Cell Viability Assay
| Cell Line: | 123 cell lines such as HCT116, NCI-1975, and HT29 cells |
| Concentration: | 0.001, 0.01, 0.1, 1, and 10 μM |
| Incubation Time: | 72 hours |
| Result: | Potently killed cells with an EC 50 range of 41 to 785 nM. |
CB-6644 (150 mg/kg, oral administration, 10 days of treatment for SCID-beige mice bearing Ramos xenograft models, 30 days of treatment for SCID-beige mice bearing RPMI8226 xenograft models) has antitumor activity in xenograft tumor models with tumor growth inhibitions (TGIs) of 68 and 81%, respectively in Ramos xenograft models and RPMI8226 xenograft models.
| Animal Model: | SCID-beige mice bearing human tumor xenografts derived from either Burkitt’s lymphoma (Ramos) or multiple myeloma (RPMI8226) cell lines |
| Dosage: | 150 mg/kg |
| Administration: | Oral gavage once (qd) or twice (BID) daily, 10 days of treatment for Ramos, 30 days of treatment for RPMI8226 |
| Result: | There was no significant bodyweight loss in mice. TGI of 68 and 81% in Ramos and RPMI8226, respectively. |
安全信息
| WGK Germany | WGK 3 |
|---|---|
| 存儲(chǔ)類(lèi)別 | 11 - 可燃固體 |
| 更新日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱(chēng) | CAS號(hào) | 包裝 | 價(jià)格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-114429 | CB-6644 CB-6644 | 2316817-88-4 | 1mg | 2800元 |
| 2026/06/05 | HY-114429 | CB-6644 CB-6644 | 2316817-88-4 | 5mg | 5600元 |